Acta Haematol

1. YOUSEFI A, Levin MD, Westerweel PE
   The Prevalence and Clinical Impact of Bone Marrow Fibrosis in Chronic Myeloid Leukemia.
   Acta Haematol. 2026 Sep 17:1-6. doi: 10.1159/000553020.
   

   >> Share

   
   

   
   Am J Hematol

2. KUMAR S, Warraich M, Fatima M, McCullough K, et al
   Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients.
   Am J Hematol. 2026 Sep 17. doi: 10.1002/ajh.70500.
   

   >> Share

   
   
3. TROUSSARD X, Maitre E, Paillassa J
   Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment.
   Am J Hematol. 2026 Sep 15. doi: 10.1002/ajh.70441.
   

   >> Share

   
   

   
   Ann Hematol

4. DUZENLI KAR Y, Oren H, Sezgin Evim M, Zengin E, et al
   Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association.
   Ann Hematol. 2026;105:422.
   

   >> Share

   
   
5. LYU C, Meng H, Pu Y, Luan X, et al
   Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.
   Ann Hematol. 2026;105:420.
   

   >> Share

   
   
6. GINOSYAN AA, Ashouri K, Cheng J, Ford L, et al
   Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival.
   Ann Hematol. 2026;105:415.
   

   >> Share

   
   
7. ALIBRAHIM MN, Elsayed MA, Alqahtani AN, Alshehri FS, et al
   Defining and managing high-risk acute myeloid leukemia (AML) in 2026.
   Ann Hematol. 2026;105:416.
   

   >> Share

   
   
8. ADNAN N
   Presenting a multi-marker response-adapted framework for venetoclax duration in acute myeloid leukemia.
   Ann Hematol. 2026;105:414.
   

   >> Share

   
   

   
   Blood

9. BERTOLI S, Landberg N, Berard E, Gondran C, et al
   Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia.
   Blood. 2026 Sep 18:blood.2026033895. doi: 10.1182/blood.2026033895.
   

   >> Share

   
   
10. 
    Sasca D, Hahnel PS, Szybinski J, et al. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood. 2014;124(1):121-133.
    Blood. 2026;148:1637-1638.
    

    >> Share

    
    
11. KENNEDY VE, Peretz CAC, Walia A, Chyla B, et al
    Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.
    Blood. 2026;148:1588-1604.
    

    >> Share

    
    

    
    Cancer

12. CHIEN KS, Garcia-Manero G
    Clinical management of clonal hematopoiesis.
    Cancer. 2026;132:e70588.
    

    >> Share

    
    
13. ZHANG J, Luo J, Shen X, Ren J, et al
    Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia-A 7-year real-world study.
    Cancer. 2026;132:e70578.
    

    >> Share

    
    
14. SENAPATI J, Abdel-Salam HM, Jdanov VD, Loghavi S, et al
    Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms.
    Cancer. 2026;132:e70613.
    

    >> Share

    
    

    
    Cancer Chemother Pharmacol

15. TANNUMSAENG S, Anurathapan U, Sermcheep A, Kanjanakan P, et al
    Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients.
    Cancer Chemother Pharmacol. 2026;96:107.
    

    >> Share

    
    

    
    Exp Hematol

16. FENG J, Hao Q, Xu M, Jia Y, et al
    Effect of the dominant-negative Ikaros isoform 6 (Ik6) on cell function and drug sensitivity in Ph-positive acute lymphoblastic leukemia cell lines.
    Exp Hematol. 2026 Sep 13:105871. doi: 10.1016/j.exphem.2026.105871.
    

    >> Share

    
    
17. KIM HN, Hurwitz S, Fourfouris T, Lee KJ, et al
    Integrin Alpha 4 Inhibition Prolongs the Survival of NSG Mice Engrafted with CD19-Negative Post-CART19 Relapsed B-ALL.
    Exp Hematol. 2026;161:105471.
    

    >> Share

    
    

    
    Int J Hematol

18. HASEGAWA K, Miyazaki T, Tanaka M, Hagihara M, et al
    Dynamic nutritional changes between relapse and second allogeneic transplantation predict survival in acute leukemia.
    Int J Hematol. 2026 Sep 18. doi: 10.1007/s12185-026-04279.
    

    >> Share

    
    
19. VOLKOV N, Moiseev I, Botina A, Zhogolev D, et al
    Cytokine release syndrome in adults with acute leukemia after allo-HCT with posttransplant cyclophosphamide prophylaxis.
    Int J Hematol. 2026 Sep 15. doi: 10.1007/s12185-026-04287.
    

    >> Share

    
    

    
    J Clin Oncol

20. POLLARD JA, Alonzo TA, Gerbing RB, Kutny M, et al
    AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group.
    J Clin Oncol. 2026;44:2590-2601.
    

    >> Share

    
    

    
    Leuk Lymphoma

21. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo-Uixeda S
    Letter to the editor regarding 'Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan'.
    Leuk Lymphoma. 2026 Sep 16:1-2. doi: 10.1080/10428194.2026.2732486.
    

    >> Share

    
    
22. DAUNOV M
    Expanding access to leukemia specialists in the venetoclax era.
    Leuk Lymphoma. 2026 Sep 13:1-3. doi: 10.1080/10428194.2026.2731270.
    

    >> Share

    
    
23. SCHOENBECK K, Wei D, Hazra NC, Constantinescu C, et al
    Adverse events, quality of life, and work impairment in patients with chronic myeloid leukemia (CML)-a survey of first- and second-line tyrosine kinase inhibitor (TKI) intolerance in the US.
    Leuk Lymphoma. 2026 Sep 13:1-11. doi: 10.1080/10428194.2026.2721033.
    

    >> Share

    
    

    
    Leuk Res

24. RESTO-SANTOS DM, Perissinotti AJ, Bixby DL, Burke PW, et al
    Treatment of acute myeloid leukemia with inv(3) or t(3;3): A single-center retrospective cohort study and literature review.
    Leuk Res. 2026;170:108319.
    

    >> Share

    
    

    
    Leukemia

25. GURU MURTHY GS, Shah B, Badar T, Leonard J, et al
    Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Leukemia. 2026 Sep 14. doi: 10.1038/s41375-026-03130.
    

    >> Share

    
    

    
    N Engl J Med

26. MYERS RM, Hunger SP
    Blinatumomab - A New Standard of Care in Acute Lymphoblastic Leukemia.
    N Engl J Med. 2026;395:1127-1129.
    

    >> Share

    
    
27. SCHRAPPE M, Locatelli F, Valsecchi MG, Zugmaier G, et al
    Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.
    N Engl J Med. 2026;395:1075-1089.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share